Transformed Follicular Lymphoma (TFL) Predicts Outcome in Advanced Endometrial Cancer
نویسندگان
چکیده
منابع مشابه
Increased vascularization predicts favorable outcome in follicular lymphoma.
PURPOSE In malignant lymphoma, angiogenesis has been associated with adverse outcome or more aggressive clinical behavior. This correlation has been established in groups of patients with a large heterogeneity regarding lymphoma subtypes and treatment regimens. The aim of this study is to investigate the significance of vascularization in patients with follicular lymphoma receiving uniform firs...
متن کاملTransformed follicular non-Hodgkin lymphoma.
Histologic transformation of follicular lymphoma to an aggressive non-Hodgkin lymphoma is a critical biologic event with profound implications on the natural history of this otherwise indolent disease. Recent insights into the genetic and epigenetic basis of transformation have been described, with the recognition of pivotal events governing the initiation and persistence of tumor evolution. Ou...
متن کاملAtypical Presentation of Transformed Follicular Lymphoma
Transformation of follicular lymphoma (FL) to Diffuse Large B-Cell Lymphoma (DLBCL) occurs commonly is and associated with a rapidly progressive clinical course that is refractory to treatment and a short survival. The clinical presentation of this transformed disease is variable. We here report a 65 years old man with an atypical presentation of transformed FL. He initially presented with symp...
متن کاملHigh expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma.
Substantial research has been dedicated to the study of the relationship between genetic mechanisms regulating cell functions in tumors and how those tumors respond to various treatment regimens. Because these mechanisms are still not well understood, we have chosen to study the genetic makeup of 57 tumor samples from patients with follicular lymphoma (FL). Our goal was to develop a prognostic ...
متن کاملRituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies
Rituximab is a chimeric monoclonal CD20 antibody used in the treatment of CD20 positive non-Hodgkin lymphomas and has revolutionized treatment approach to these hematologic malignancies in the last decade. The main aim of this review is to present data on the use of rituximab in the treatment of follicular lymphoma (FL). We will focus on rituximab maintenance strategies in the first and second ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Epidemiology Biomarkers & Prevention
سال: 2018
ISSN: 1055-9965,1538-7755
DOI: 10.1158/1055-9965.epi-17-0762